242 filings
Page 5 of 13
8-K
2wt96uiltd5mq
10 Sep 20
Other Events
4:39pm
8-K
fwvtt19z
9 Sep 20
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
9:30am
8-K
zn00qgkvrzlehp6h4g01
4 Sep 20
Diffusion Pharmaceuticals Appoints
4:01pm
8-K
dqaw5req tk8u8pfb
10 Aug 20
Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
5:00pm
8-K
nkj6p vyhl
29 Jul 20
Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC
8:14am
8-K
dt05ho6
7 Jul 20
Phase 1b dosing expected to begin this month
4:38pm
8-K
fsj6qum5boes
17 Jun 20
Submission of Matters to a Vote of Security Holders
4:37pm
8-K
8qvmv7wgy3b813mc44ff
12 Jun 20
Dosing expected to begin in Q2 2020 with first data in Q3 2020
12:18pm
8-K
qfypvo 4xaut1u18dokf
1 Jun 20
Other Events
4:40pm
8-K
gqr1 dwws1x3
26 May 20
Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program
4:45pm
8-K
h6knxenhs2adu
20 May 20
Other Events
5:27pm
8-K
ope98r4 6gu
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
munriwsul0mt
11 May 20
Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
4:58pm
8-K
yjl1 8u52k7y4r2di
8 May 20
Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS
4:40pm
8-K
yfe xdbcjrj
6 May 20
Entry into a Material Definitive Agreement
9:05am
8-K
l8aonjowo2x0rir wghh
29 Apr 20
Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19
8:44am
8-K
i3t t8aaw
1 Apr 20
Partnering with University of Virginia Health and iTHRIV
4:41pm
8-K
qgxzio92z5dhz5qz
24 Mar 20
Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the Coronavirus
4:41pm
8-K
rtk0u
18 Mar 20
Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer
5:22pm
8-K
0ydb4xs1 xl347
6 Feb 20
Departure of Directors or Certain Officers
4:39pm